Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Kiniksa Pharmaceuticals Ltd KNSA

Healthcare Biotechnology
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:KNSA)

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire 3 days ago

Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

GlobeNewswire 9 days ago

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

GlobeNewswire April 2, 2024

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution

GlobeNewswire February 28, 2024

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

GlobeNewswire February 21, 2024

Kiniksa Pharmaceuticals Provides Corporate Update

GlobeNewswire January 4, 2024

Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2024

Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution

GlobeNewswire October 31, 2023

Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023

GlobeNewswire October 24, 2023
View More News ››

Opinion & Analysis (NDAQ:KNSA)

Kiniksa Shares Trade Up 30% on COVID-19 Pneumonia and Hyperinflammation Treatment

Streetwise Reports April 1, 2020

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug

Streetwise Reports November 21, 2019
View More Opinion ››

Bullboard Posts (NDAQ:KNSA)

Be the first to post on this bullboard.

Safe Supply Streaming Co Ltd.

Safe Supply Streaming Co Ltd.

Safe Supply Streaming Co Ltd. is engaged in investing in the legal and regulated supply of drugs. The Company’s focus is ...
View More »